ReviewO&G open2025
Yield of RASopathy Gene Panel in Karyotype-Normal or Microarray-Normal Fetuses With Increased Nuchal Translucency: A Systematic Review and Meta-Analysis.
Review in O&G open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo characterize the diagnostic yield of RASopathy gene panels performed due to increased nuchal translucency (NT) measurements with normal karyotype or chromosomal microarray (CMA) results or both. DATA SOURCES: PubMed, OVID, SCOPUS, CINAHL, and ClinicalTrials.gov databases were searched from inception through January 8, 2025 (PROSPERO CRD 42023353582). METHODS OF STUDY SELECTION: Studies were deemed eligible for inclusion if the cohort consisted of fetuses with increased NT with normal karyotype or CMA or both that were tested with a targeted RASopathy gene panel. Quality assessment and critical appraisal of included studies were independently conducted using the Quality Assessment tool for Diagnostic Accuracy Studies. The primary outcome was the diagnostic yield of a RASopathy gene panel in fetuses with increased NT and normal karyotype or CMA or both. Nuchal translucency measurement, associated congenital abnormalities, the presence of cystic hygroma, and the number of genes evaluated in each study were collected. TABULATION INTEGRATION AND
resultsOur systematic review identified 1,800 cases that met inclusion criteria across 14 studies. The RASopathy gene panel identified a diagnostic variant in 114 cases, for an overall yield of 8.1% (0.081, 95% CI, 0.036-0.139). In fetuses with isolated increased NT, the RASopathy gene panel identified a diagnostic variant in 3.3% of cases (0.033, 95% CI, 0.006-0.074). In fetuses with additional ultrasound abnormalities, the RASopathy gene panel identified a diagnostic variant in 15.1% of cases (0.151, 95% CI, 0.011-0.381). Cardiac abnormalities were the most common associated finding. When a cystic hygroma was identified, total diagnostic yield was 18.4% (0.184, 95% CI, 0.110-0.270).
conclusionTesting for RASopathies with a targeted gene panel identified a diagnostic variant in 3.3% with isolated increased NT and 15.1% with nonisolated increased NT after normal karyotype or CMA or both. SYSTEMATIC REVIEW REGISTRATION: PROSPERO, CRD42023353582.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.